Skip to main content

Dipeptidyl peptidase-4 inhibitors

31-08-2023 | Type 2 diabetes | News

Pragmatic trial suggests best cardioprotective agents for type 2 diabetes

SGLT2 inhibitors and GLP-1 receptor agonists appear to offer the best protection against major adverse cardiovascular events in people with type 2 diabetes.

03-02-2023 | Empagliflozin | News

DINAMO: Empagliflozin shows promise for young people with type 2 diabetes

Empagliflozin, but not linagliptin, provides “clinically relevant” improvements in glycemic control versus placebo in children and adolescents with type 2 diabetes, report the DINAMO investigators.

Close up of mixed medications

09-12-2022 | Medications | News

TriMaster data support ‘try before you choose’ for type 2 diabetes medications

Allowing people to try out medications for type 2 diabetes and choose their preferred one is a viable approach in the absence of a clear clinical indication, say the TriMaster investigators.

Close up of doctor explaining treatment methods to patient

05-12-2022 | SGLT2 inhibitors | News

Algorithm could optimize SGLT2 vs DPP-4 inhibitor decisions in clinical practice

An algorithm based on real-world clinical data could support decisions between use of SGLT2 inhibitors and DPP-4 inhibitors in people with type 2 diabetes.

06-10-2022 | SGLT2 inhibitors | News

SGLT2 inhibitors linked to lower gout risk than DPP-4 inhibitors

SGLT2 inhibitors are associated with a lower risk for gout than DPP-4 inhibitors, research suggests.

Doctor holds in his hands the kidney concept

01-09-2022 | Metformin | News

People with type 2 diabetes and CKD missing out on renoprotective drugs

People with type 2 diabetes and chronic kidney disease are substantially less likely to initiate SGLT2 inhibitors than those with normal kidney function, despite their proven renoprotective benefits, research shows.

25-08-2022 | Physical activity | News

Initiating glucose-lowering therapy may be linked to a reduction in physical activity

Starting treatment with SGLT2 inhibitors, GLP-1 receptor agonists, or DPP-4 inhibitors is associated with a reduction in physical activity levels among some people with type 2 diabetes, researchers report.

30-06-2022 | Adverse effects | News

Meta-analysis flags cholecystitis risk with DPP-4 inhibitor treatment

People taking dipeptidyl peptidase-4 inhibitors to treat type 2 diabetes may have an increased risk for cholecystitis, especially with longer duration of treatment, show findings of a meta-analysis.